>>MOUNTAIN VIEW, Calif., Jan. 27 /PRNewswire/ -- Perlegen Sciences, Inc. today announced the closing of a $30 million private placement of its Series C Preferred Stock with new and existing investors. The financing was led by Maverick Capital, and new investors included Unilever Technology Ventures, Eli Lilly & Co., Biofrontier Partners and CSK Venture Capital. Previous investors also participating in the financing included Vulcan Ventures, BioMedical Sciences Investment Fund, CMEA Ventures, SB Life Science Ventures, Dr. Alejandro Zaffaroni and others.
"This equity financing will enable us to accelerate Perlegen's discovery of the genetic basis of serious diseases," said Brad Margus, Chief Executive Officer of Perlegen. "Through our internal research programs, the whole genome association studies we conduct with corporate partners and our collaborations with government and academic researchers, Perlegen will identify many insights that will help in treating a wide range of diseases."<<
snip
Cheers, Tuck |
